Bleeding Disorders — Causes, Symptoms & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Bleeding disorders are conditions that impair the body's ability to form a stable blood clot (haemostasis), resulting in excessive, prolonged, or spontaneous bleeding following injury or surgery, or — in severe cases — without apparent cause. Normal haemostasis requires intact blood vessel walls, functional platelets (primary haemostasis), and a coordinated coagulation cascade of clotting factors (secondary haemostasis) producing a stable fibrin clot. Disorders may affect any of these components. Major categories include: inherited coagulation factor deficiencies (hemophilia A — factor VIII; hemophilia B — factor IX; hemophilia C — factor XI; rare factor deficiencies); von Willebrand disease (VWD — the most common inherited bleeding disorder, affecting 1% of the population — involves deficiency or dysfunction of von Willebrand factor, a protein critical for platelet adhesion and factor VIII stabilisation); platelet disorders (immune thrombocytopenic purpura/ITP, drug-induced thrombocytopenia, platelet function disorders such as Glanzmann thrombasthenia, Bernard-Soulier syndrome); and acquired coagulopathies (liver disease, vitamin K deficiency, disseminated intravascular coagulation, anticoagulant medications).

Inherited bleeding disorders result from genetic mutations: hemophilia A (factor VIII gene mutations on the X chromosome — X-linked recessive, predominantly males) and hemophilia B (factor IX gene — X-linked recessive). Von Willebrand disease type 1 (quantitative deficiency — autosomal dominant, 80% of cases), type 2 (qualitative variants — multiple subtypes), and type 3 (complete absence — autosomal recessive, severe). Platelet function disorders include Glanzmann thrombasthenia (integrin alphaIIbbeta3 deficiency — autosomal recessive) and Bernard-Soulier syndrome (GPIb-IX-V deficiency). Acquired bleeding disorders arise from: liver disease (reduced synthesis of all coagulation factors except factor VIII and von Willebrand factor); vitamin K deficiency (warfarin therapy, malabsorption, newborn haemorrhagic disease); disseminated intravascular coagulation (DIC — sepsis, trauma, obstetric emergencies, malignancy causing simultaneous clotting and bleeding); immune thrombocytopenia (ITP — autoantibodies against platelet glycoproteins, destroying platelets); thrombotic thrombocytopenic purpura (TTP — ADAMTS13 deficiency causing microthrombi); heparin-induced thrombocytopenia (HIT — paradoxical pro-thrombotic state); and medication-induced thrombocytopenia (quinine, vancomycin, penicillin).

Bleeding pattern varies by disorder type. Platelet and von Willebrand factor defects cause mucocutaneous bleeding: easy bruising, prolonged bleeding from cuts, frequent nosebleeds (epistaxis), heavy menstrual periods (menorrhagia — VWD is the most common cause of heavy periods requiring investigation), gum bleeding after dental work, and petechiae (tiny pinpoint skin haemorrhages with very low platelet counts). Coagulation factor deficiencies (hemophilia) cause deep tissue bleeding: haemarthroses (joint bleeding — painful swelling of knees, elbows, and ankles), muscle haematomas (particularly iliopsoas — severe pain with hip flexion), and post-surgical or post-traumatic bleeding hours after initial haemostasis. Intracranial haemorrhage is the most life-threatening complication of severe hemophilia. DIC presents with simultaneous bruising and bleeding from multiple sites combined with thrombosis. Unexplained bruising in children must be evaluated to exclude non-accidental injury alongside bleeding disorders.

Initial haemostasis screening includes: full blood count with platelet count (thrombocytopenia indicates platelet or bone marrow issue); prothrombin time (PT/INR) — assesses extrinsic and common pathway (factors I, II, V, VII, X); activated partial thromboplastin time (APTT) — assesses intrinsic and common pathway (factors I, II, V, VIII, IX, X, XI, XII); prolonged APTT with normal PT suggests hemophilia or VWD; prolonged PT with normal APTT suggests factor VII deficiency or warfarin effect; both prolonged suggests common pathway defect, liver disease, or DIC. Specific tests: von Willebrand factor antigen (VWF:Ag), VWF activity (ristocetin cofactor — VWF:RCo), and VWF multimers to distinguish VWD subtypes. Factor VIII activity (hemophilia A), factor IX activity (hemophilia B). Platelet function analyser (PFA-100) screens for platelet dysfunction. ADAMTS13 activity (reduced in TTP — emergency diagnosis). Mixing studies with normal plasma correct APTT in factor deficiency but not with inhibitors (antibodies). Bethesda assay quantifies inhibitor titre in hemophilia with neutralising antibodies. Bleeding assessment tool (ISTH-BAT) standardises bleeding history to guide investigation.

Treatment is tailored to the specific disorder and severity. Hemophilia A: prophylactic factor VIII concentrate infusions 2-3 times weekly to prevent joint disease; extended half-life factor VIII (Eloctate, Elocta) reduces infusion frequency; emicizumab (Hemlibra — bispecific antibody) given subcutaneously weekly to monthly is highly effective for hemophilia A including patients with inhibitors. Hemophilia B: factor IX concentrate; extended half-life factor IX products allow weekly or fortnightly dosing; fitusiran (siRNA silencing antithrombin) and concizumab reduce bleeding in hemophilia B with or without inhibitors. Gene therapy (valoctocogene roxaparvovec for hemophilia A; etranacogene dezaparvovec for hemophilia B) has achieved sustained factor expression in clinical trials and received regulatory approval. Von Willebrand disease: DDAVP (desmopressin — releases endogenous VWF from endothelial stores) for type 1 VWD — given IV, intranasal (Stimate) or subcutaneous before procedures; VWF concentrate (Haemate P, Wilate) for VWF-deficient types; tranexamic acid prevents fibrinolysis in mucosal bleeding (menorrhagia, dental procedures). ITP: observation for mild thrombocytopenia (platelets >30 x10^9/L with no bleeding); oral prednisolone first-line; IV immunoglobulin for rapid platelet rise; rituximab; thrombopoietin receptor agonists (eltrombopag, romiplostim) for refractory ITP; splenectomy as a last resort. TTP: emergency plasma exchange and steroids — delay causes fatal outcome. Vitamin K deficiency: phytomenadione (vitamin K1) IV or oral.

Recurrent haemarthroses in untreated severe hemophilia cause progressive haemophilic arthropathy — permanent joint destruction, deformity, contractures, and disability requiring joint replacement surgery at a young age. Intracranial haemorrhage carries high mortality and leaves survivors with permanent neurological deficits. Deep muscle haematomas, particularly iliopsoas, cause chronic pain, femoral nerve palsy, and hip contractures. Uncontrolled menorrhagia in von Willebrand disease leads to severe iron deficiency anaemia requiring blood transfusion. In DIC, simultaneous thrombosis and haemorrhage cause multi-organ failure with mortality exceeding 30-50% in severe cases. Women with undiagnosed VWD suffer significantly higher rates of postpartum haemorrhage requiring emergency intervention. Patients with ITP who develop platelet counts below 10 x10^9/L risk life-threatening spontaneous intracranial or gastrointestinal haemorrhage. Historically, use of non-virus-inactivated clotting factor concentrates caused widespread HIV and hepatitis C epidemics in hemophilia patients before the 1990s — modern recombinant products and viral inactivation have eliminated this risk.

For hereditary disorders, genetic counselling enables informed reproductive decisions and carrier detection. Preimplantation genetic diagnosis (PGD) allows selection of unaffected embryos during IVF. Primary prophylaxis with clotting factor concentrates started early in severe hemophilia (before the first joint bleed) prevents haemophilic arthropathy — the major long-term complication of untreated hemophilia. All patients with hemophilia should be registered with a Haemophilia Treatment Centre for comprehensive multidisciplinary care. Avoid aspirin, NSAIDs, and anticoagulants unless under specialist guidance. Dental prophylaxis and prompt management of dental disease prevents difficult oral bleeding episodes. For acquired disorders: monitor INR regularly in warfarin-treated patients; use vitamin K prophylaxis in all newborns to prevent haemorrhagic disease of the newborn; treat underlying sepsis or obstetric emergency to prevent DIC. Medical alert identification should be worn by all patients with significant bleeding disorders.

Go to the emergency department immediately for: suspected intracranial haemorrhage (sudden severe headache, weakness, vision changes, or altered consciousness) in a known bleeding disorder patient — this is a haematological emergency requiring immediate factor replacement before imaging; bleeding from a major joint causing severe pain and swelling; serious trauma in any patient with a coagulation disorder; and simultaneous unexplained bruising and thrombosis (suggesting DIC or TTP). Contact a haematologist or haemostasis service urgently before any surgical or dental procedure if you have a known or suspected bleeding disorder. Women with heavy menstrual bleeding and iron deficiency anaemia, or unexplained bruising in childhood, should be investigated for von Willebrand disease and platelet disorders — these are frequently underdiagnosed, particularly in women.